Quantcast

Latest Alkynes Stories

2010-02-17 07:36:47

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial data were reported in a new study published online February 16 in the Journal of the National Cancer Institute. Natasha B. Leighl, M.D., of the University Health Network in Toronto, Canada, and...

2009-12-17 15:08:00

Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO) The Drug Evaluation and Research Oncologic Drugs Advisory Committee (ODAC), a panel of independent medical and scientific experts and...

2009-09-29 06:50:00

SAN FRANCISCO, Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced findings of a double-blind study which demonstrate that GELNIQUE was comparable to placebo in its effect on memory tests and other cognitive functions in older healthy adult subjects when compared to immediate release oral oxybutynin treatments. The results were presented at the International Continence Society's Annual...

2009-09-01 15:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. The 20...

8c6e0fd2f47667a9b9bbdf7b297b168c1
2009-08-26 12:55:00

The century-old challenge of transporting acetylene may have been solved in principle by a team of scientists working at the National Institute of Standards and Technology (NIST). A NIST research team has figured out* why a recently discovered material can safely store at low pressure up to 100 times as much of the volatile chemical as can be done with conventional methods.The team has probed the atomic-level workings of a metal-organic framework (MOF), a lattice-like structure made of copper...

2009-08-03 07:00:00

RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 is the first orally-administered irreversible dual inhibitor of EGFR and HER2,(1) to reach...

64cc0f389f6e6a622a9425e1a3fc25751
2009-06-17 12:50:00

New research shows that the anti-cancer properties of carrots are more potent if the vegetable is not cut up before cooking, BBC News reported."Boiled before cut" carrots were found to contain up to 25 percent more of the anti-cancer compound falcarinol than those that were first chopped up, scientists said.The Newcastle University researchers, who will present their findings in France at the NutrEvent conference on nutrition and health, gave falcarinol to lab rats and found that they develop...

e3ee029267b363ee362c969a267b606c1
2009-05-31 09:25:00

The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday. Patients given Tarceva, made by the Swiss manufacturer Roche, and Avastin, saw their cancer growth halt more than a different group given just Avastin. 750 patients were randomly selected and given either Avastin and a placebo, or Avastin and Tarceva. The Tarceva group lived about 4.8 months before the cancer grew again,...

2008-11-07 12:00:23

Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.